exRNAdisease

Entry Detail

---



General Information

Database ID: exR0088229 RNA Name: hsa-miR-3648 RNA Type: miRNA Chromosome: chr21 Starnd: + Coordinate: Start Site(bp): 8987026 End Site(bp): 8987046 External Links: hsa-miR-3648

Disease Information

Disease Name: Breast Cancer Disease Category: Cancers MeSH ID: D001943 Type: Neoplasms/Breast Neoplasms Alias: Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID: GSE101841 Description: Serum microRNA profile of Her2 positive metastatic breast cancer patients Experimental Design: Trastuzumab therapy Case Disease Type: Breast Cancer Case Disease SubType: HER2 positive metastatic breast cancer Case Sample: Breast Cancer Trastuzumab resistant Control Sample: Trastuzumab sensitive Number of Case: 42 Number of Control: 61 Number of Samples: 103

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand MT-CO2 chrMT 7586 8269 + THAP7 chr22 20999104 21002196 - CERS4 chr19 8206736 8262421 + ARL8B chr3 5122245 5180912 + EEF1G chr11 62559596 62574086 - FNBP4 chr11 47716494 47767443 - PTGES3 chr12 56663341 56688408 - AP002990.1 chr11 62559603 62591531 - PTCH2 chr1 44819844 44843253 - MAPK9 chr5 180233143 180292099 - ACTG1 chr17 81509971 81523847 - ECPAS chr9 111360692 111484745 - RNF126 chr19 647526 663233 - SF3A2 chr19 2236824 2248655 + TPT1 chr13 45333471 45341370 - AKIRIN2 chr6 87674860 87702233 - LZTS3 chr20 3162617 3173592 - AL133352.1 chr10 100505628 100529881 - ATP6V0A2 chr12 123712353 123761755 + SET chr9 128683424 128696400 + SH3GLB2 chr9 129007036 129028303 - PAM16 chr16 4331549 4355607 - LRRC45 chr17 82023305 82031151 + SRRM2 chr16 2752626 2772538 + NDUFB8 chr10 100523740 100530000 - GAPDH chr12 6534512 6538374 + CORO7-PAM16 chr16 4340251 4420494 - SKI chr1 2228319 2310213 + SSR2 chr1 156009048 156020951 - ARRDC4 chr15 97960703 97973833 + miRNA targets: NA circRNA targets: NA lncRNA targets: NA Display:

Experiment Detail

GEO ID: GSE101841 Sample Source: Blood Source Fraction: Serum Platform: GPL23138 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 1808 Sample treatment protocol: NA RNA Extract protocol: Total RNA was extracted from 103 samples with the Plasma RNA Purification Mini Kit (51000, NorgenBiotek Corporation, Canada), following manufacturer's instructions. RNA library preparation protocol: Total RNA extracted from 600ul serum was employed with 100 nmol/L of pCp-DY647 and 15 Units of T4 RNA ligase in a total reaction volume of 20 ul at 16°C overnight.

Reference

PMID: 29691399 Title: A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients. Author: Li H, Liu J, Chen J, Wang H, Yang L, Chen F, Fan S, Wang J, Shao B, Yin D, Zeng M, Li M, Li J, Su F, Liu Q, Yao H, Su S, Song E Journal: Nat Commun. 2018 Apr 24;9(1):1614. Description: MicroRNAs (miRNAs) have been used to predict therapeutic effects for various cancers, but whether miRNAs can serve as biomarkers for HER2+ metastatic breast cancer (MBC) patients remains unclear.